Alpha Signal Monitor - Daily Market Briefing | December 31, 2025
Daily Market Research Report
December 31, 2025
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Institutional outlook on GLD/IAU/BAR (gold ETFs) as of December 31, 2025
Trading Idea: Buy (overweight gold ETFs such as GLD, IAU, BAR) Rationale (TL;DR): Most major houses keep or have raised bullish gold targets into 2026 on persistent central‑bank demand, renewed ETF inflows, and expectations of lower real yields. A minority (Citi) is tactically cautious near‑term, but the modal view supports staying long gold via liquid ETFs.
Gold set repeated records in 2025 amid rate cuts, geopolitical/trade uncertainty, and strong official-sector buying; prices ended the year near highs, with momentum expected to carry into 2026 if real yields ease further.
Key Drivers - Central‑bank accumulation and renewed ETF inflows underpin demand and price floor. - Expectations for additional Fed easing and lower real yields increase gold’s relative appeal vs. yielders. - Policy/trade uncertainty and reserve diversification (de‑dollarization) continue to boost strategic allocations to gold. - Producers unlikely to respond with a rapid supply super‑cycle; supply elasticity remains low.
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Bullish | Raised Dec 2026 target to $4,900/oz (prior $4,300); team also flagged mid‑2026 ~$4,000 earlier in 2025. | GS cites strong Western ETF inflows and sustained central‑bank buying as key drivers; easing policy supports additional demand. | 2025-10-07 | - |
| Morgan Stanley | Bullish | Sees ~$4,500/oz by mid‑2026; CIO also advocated a 60/20/20 allocation with gold as a core hedge in 2025. | MS notes continued ETF/official demand with scope for further gains into 2026 despite pullbacks; CIO emphasized gold’s superior hedging role vs. long Treasuries. | 2025-10-31 | - |
| JP Morgan | Bullish | Forecasts gold to average ~$5,055/oz in 4Q26, pushing toward ~$5,000 by YE 2026; upside scenario extends beyond. | JPM sees persistent investor and central‑bank diversification into gold, aided by Fed cutting cycle and elevated policy risks. | 2025-12-16 | - |
| Bank of America | Bullish | Raised 2026 outlook to $5,000/oz (avg ~ $4,400). | BofA argues that a ~14% rise in investment demand similar to 2025 could lift gold to $5,000; acknowledges scope for near‑term corrections. | 2025-10-13 | - |
| Citigroup | Neutral/Cautious near‑term | Lowered 0–3M target to ~$3,800/oz (Oct 28, 2025); medium‑term 2026 avg around ~$3,250/oz in Reuters tallies. | Citi warns that the ‘litany of worries’ may need to persist to sustain the bull run; sees risk of softer investment demand into late‑2025/2026. | 2025-10-28 | - |
| UBS | Bullish (Most Preferred) | Targets ~$4,500/oz by June 2026; CIO stays long gold in global allocation. | UBS cites structural demand from central banks/ETFs and lower real yields; continues to recommend strategic gold exposure. | 2025-11-27 | - |
| HSBC | Bullish | Raised 2025 average to ~$3,455/oz; 2026 average ~$4,600/oz with potential spike to ~$5,000/oz in 1H26. | HSBC expects the bull market to extend into early‑2026 on geopolitical/economic risks and public‑debt concerns, with new buyers likely to stay engaged. | 2025-10-17 | - |
| Deutsche Bank | Bullish | Raised 2026 forecast to $4,450/oz (range $3,950–$4,950). | DB highlights stabilizing investor flows and persistent official‑sector demand absorbing supply; sees ~$3,900/oz floor from ETF flows. | 2025-11-26 | - |
Risk Considerations - Fewer or delayed Fed cuts/higher real yields could pressure gold and spur ETF outflows. - A slowdown in official‑sector buying or reversal of ETF flows would weaken the floor under prices. - Rapid de‑escalation of geopolitical/trade risks could trim safe‑haven bids. - A stronger USD or faster growth than expected could cap gains. - Exchange margin hikes and positioning washouts can amplify short‑term drawdowns.
Consensus skew is bullish into 2026. For GLD/IAU/BAR, maintain Buy with a bias to add on pullbacks; monitor Fed path, USD, and official‑sector/ETF flows as the key validation signals.
Stock Ratings
Error retrieving stock ratings information: Connection error.
IPO Calendar
Timeframe: January 1–31, 2026 (US equity markets)
As of December 31, 2025, there are no US IPOs formally scheduled for the first week of January on the major free calendars (these typically populate only when roadshows launch); historically the market tends to restart later in January after the holiday lull. Late-December SEC filings suggest an early-2026 wave led by healthcare, tech/AI and energy: Medtronic’s diabetes spin-off MiniMed (Nasdaq: MMED), Motive Technologies (NYSE: MTVE), radiopharma developer Aktis Oncology, and ARKO Petroleum all filed to go public and could begin marketing in January subject to SEC review and market windows. Broader context: 2025 was the strongest US listings year since 2021 by capital raised on Nasdaq ($46.65B), and Renaissance Capital’s 2026 outlook anticipates 200–230 IPOs raising $40–$60B, with interest in AI, fintech, healthtech and defense likely to persist. One cross‑current to watch is tighter scrutiny of very small offerings after a surge of micro‑IPOs in 2025.
MiniMed Group, Inc. (Medtronic Diabetes spin-off) (MMED)
- Expected listing date: January 2026 (TBD)
- Exchange: Nasdaq Global Select Market
- Lead underwriters: Goldman Sachs, BofA Securities, Citigroup, Morgan Stanley
- Business summary: Diabetes care company offering insulin pumps, continuous glucose monitoring and related software/consumables; being separated from Medtronic, with IPO proceeds expected to help recapitalize the stand‑alone business before a subsequent split‑off.
- Notes: Filed a Form S‑1 on December 19, 2025; price range and share count not yet disclosed; timing subject to SEC effectiveness and market conditions.
- Sources: https://www.sec.gov/Archives/edgar/data/2062583/000162828025058231/minimedgroupincs-1.htm, https://www.prnewswire.com/news-releases/medtronic-announces-filing-of-ipo-registration-statement-for-diabetes-business-minimed-302647315.html, https://www.reuters.com/business/healthcare-pharmaceuticals/medtronics-minimed-files-us-ipo-2025-12-19/
Motive Technologies, Inc. (MTVE)
- Expected listing date: January 2026 (TBD)
- Exchange: New York Stock Exchange
- Lead underwriters: J.P. Morgan, Citigroup, Barclays, Jefferies
- Business summary: AI platform for physical operations (fleet/asset management, safety and spend) serving logistics, construction, energy and other sectors; filing highlights ARR growth and enterprise adoption.
- Notes: Public S‑1 filed December 23, 2025; company release confirms proposed NYSE:MTVE; terms to be set at roadshow launch; timing subject to SEC review and markets.
- Sources: https://www.sec.gov/Archives/edgar/data/1646681/000162828025058773/motive-sx1.htm, https://gomotive.com/motive-files-registration-statement-for-proposed-initial-public-offering/, https://www.reuters.com/technology/motive-technologies-files-us-ipo-2025-12-23/
Aktis Oncology, Inc. (AKTI)
- Expected listing date: January 2026 (TBD)
- Exchange: Nasdaq Global Market
- Lead underwriters: J.P. Morgan, BofA Securities, Leerink Partners, TD Cowen
- Business summary: Clinical‑stage radiopharmaceuticals company developing targeted alpha therapies for solid tumors; part of the late‑2025 resurgence in biotech filings.
- Notes: Filed for a US IPO on December 19, 2025; S‑1 materials indicate applied ticker “AKTI”; size and range not yet set; subject to SEC review and market windows.
- Sources: https://www.sec.gov/Archives/edgar/data/2035832/000095012325005856/filename1.htm, https://www.sec.gov/Archives/edgar/data/2035832/000119312525326780/d875386dex11.htm, https://www.reuters.com/business/healthcare-pharmaceuticals/aktis-oncology-files-us-ipo-biotech-listings-rebound-2025-12-19/
ARKO Petroleum Corp. (APC)
- Expected listing date: January 2026 (TBD)
- Exchange: Nasdaq
- Lead underwriters: UBS Investment Bank, Raymond James, Stifel, Mizuho Securities, Capital One Securities
- Business summary: Wholesale fuel distributor carved out of ARKO Corp.; supplies dealers, fleet fueling and ARKO retail sites under long‑term contracts; strategy emphasizes steady cash generation and dividends.
- Notes: Filed Form S‑1 on December 19, 2025; has applied to list as “APC”; pricing terms not yet disclosed; timeline dependent on SEC effectiveness and market conditions.
- Sources: https://www.sec.gov/Archives/edgar/data/2080921/000119312525325826/d928360ds1.htm, https://www.nasdaq.com/press-release/arko-corp-announces-filing-registration-statement-proposed-initial-public-offering, https://archive.ph/2025.12.22-114228/https://www.reuters.com/business/energy/arko-petroleum-files-us-ipo-2025-12-19/
Libera Gaming Operations, Inc. (LBRJ)
- Expected listing date: January 2026 (TBD)
- Price range: $4.00–$6.00
- Shares offered: 1,300,000 shares
- Exchange: Nasdaq
- Lead underwriters: D. Boral Capital, Sutter Securities
- Business summary: Operator of pachinko/pachislot gaming halls in Japan (11 locations as of March 2024); pursuing a small US listing.
- Notes: Listed by Renaissance Capital as an upcoming Nasdaq IPO; no trade date posted as of December 31, 2025; micro‑cap terms subject to change or delay.
- Sources: https://www.renaissancecapital.com/Profile/LBRJ/Libera-Gaming-Operations/IPO, https://www.renaissancecapital.com/IPO-Center/Calendar
D. Boral Acquisition I Corp. (SPAC) (DBCAU)
- Expected listing date: January 2026 (TBD)
- Price range: $10.00 per unit
- Shares offered: 25,000,000 units
- Exchange: Nasdaq
- Lead underwriters: D. Boral Capital
- Business summary: Blank‑check company targeting businesses with enterprise value of $700M+; units include common stock and half‑warrants.
- Notes: Filed November 18, 2025; timing and final size subject to market conditions; SPAC listings may accelerate if January windows open.
- Sources: https://www.renaissancecapital.com/IPO-Center/News/115016/SPAC-D.-Boral-Acquisition-I-files-for-a-%24250-million-IPO-led-by-D.-Boral-Ca, https://www.renaissancecapital.com/Profile/DBCAU/D-Boral-Acquisition-I/IPO
This calendar reflects deals either formally scheduled or reasonably expected to target January 2026 based on late‑December filings and exchange calendars available as of December 31, 2025. Dates for “expected” offerings are placeholders until a roadshow launches and an exchange posts a trade date. IPO timing is highly sensitive to SEC review status and market conditions; consult exchange calendars and issuer/underwriter announcements for updates.
Sources
- IPO Calendar: https://archive.ph/2025.12.22-114228/https://www.reuters.com/business/energy/arko-petroleum-files-us-ipo-2025-12-19/, https://gomotive.com/motive-files-registration-statement-for-proposed-initial-public-offering/, https://www.nasdaq.com/press-release/arko-corp-announces-filing-registration-statement-proposed-initial-public-offering, https://www.prnewswire.com/news-releases/medtronic-announces-filing-of-ipo-registration-statement-for-diabetes-business-minimed-302647315.html, https://www.renaissancecapital.com/IPO-Center/Calendar, https://www.renaissancecapital.com/IPO-Center/News/115016/SPAC-D.-Boral-Acquisition-I-files-for-a-%24250-million-IPO-led-by-D.-Boral-Ca, https://www.renaissancecapital.com/Profile/DBCAU/D-Boral-Acquisition-I/IPO, https://www.renaissancecapital.com/Profile/LBRJ/Libera-Gaming-Operations/IPO, https://www.reuters.com/business/healthcare-pharmaceuticals/aktis-oncology-files-us-ipo-biotech-listings-rebound-2025-12-19/, https://www.reuters.com/business/healthcare-pharmaceuticals/medtronics-minimed-files-us-ipo-2025-12-19/, https://www.reuters.com/technology/motive-technologies-files-us-ipo-2025-12-23/, https://www.sec.gov/Archives/edgar/data/1646681/000162828025058773/motive-sx1.htm, https://www.sec.gov/Archives/edgar/data/2035832/000095012325005856/filename1.htm, https://www.sec.gov/Archives/edgar/data/2035832/000119312525326780/d875386dex11.htm, https://www.sec.gov/Archives/edgar/data/2062583/000162828025058231/minimedgroupincs-1.htm, https://www.sec.gov/Archives/edgar/data/2080921/000119312525325826/d928360ds1.htm
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2025-12-31 at 11:25 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI